Editorials

Local resection of posterior uveal melanoma

Although enucleation was once considered to be the only acceptable management for malignant melanoma of the posterior uvea (ciliary body and choroid), in recent years it has become controversial. This controversy over enucleation has contributed to the popularity of several other therapeutic methods. Depending on a number of clinical factors, current options to enucleation for uveal melanoma include a period of observation without interventional treatment, plaque radiotherapy, charged particle irradiation, trans-scleral lamellar resection, laser photocoagulation, and transpupillary thermotherapy. In this issue of the BJ O, Damato, Paul, and Foulds describe in two articles their further observations on trans-scleral resection of posterior uveal melanoma. Since this technique is difficult, it is only used in a few centres and it is not employed as commonly as other methods such as enucleation or plaque radiotherapy. Our group has used a technique of local resection of posterior uveal tumours that is quite similar to that of Damato and colleagues, and we agree that it is the preferred treatment in selected cases. We have now resected more than 250 tumours which involved the ciliary body and/or choroid and are generally impressed with the results.

Their first report (p 102) deals with risk factors for residual and recurrent tumour after trans-scleral local resection. It is not surprising that a melanoma which is located more posteriorly carries a greater chance of residual tumour after surgery because of the technical difficulty of removing tumours that are located very close to the optic disc and fovea. It is likewise not surprising that a larger tumour, located more posteriorly and of a more malignant cell type, has a greater chance of delayed local recurrence.

An interesting observation of these authors was that a lack of adjunctive plaque radiotherapy was associated with a greater chance of local tumour recurrence. Consequently, the authors suggest that supplemental plaque radiotherapy, laser photocoagulation, or cryotherapy should be employed routinely after local resection of uveal melanoma. This planned use of more than one modality reflects a new concept that is beginning to develop in the management of uveal melanoma. In the past, the ocular oncologist who managed a uveal melanoma would select a single method, such as enucleation, radiotherapy, local resection, or perhaps other treatments. Much has been written about the indications for each of these single modalities. However, little has been mentioned about planned combined therapeutic approaches. The planned use of local resection and plaque radiotherapy, as suggested by Damato and colleagues, is an example of such a combined therapeutic approach.

Our experience on the Oncology Service at Wills Eye Hospital also suggests that planned combined methods may be preferable in selected cases. It is becoming more common for us purposely to select a combination of these methods as part of the initial plan. For example, numerous patients have been treated with plaque radiotherapy followed by low energy, long exposure laser photocoagulation as advocated by Foulds and Damato. More frequently today, we employ plaque radiotherapy combined with transpupillary thermotherapy as recently proposed by Oosterhuis and associates. For tumours that are to be managed by local resection, we frequently plan to use plaque radiotherapy as supplemental treatment. Pre-enucleation radiotherapy is sometimes employed for patients who are to undergo enucleation for larger uveal tumours. In patients who are considered high risk for metastasis, enucleation combined with chemotherapy is currently being assessed. The observations of Damato and associates have supported our current belief that planned combined treatments may have a significant future role in the management of uveal melanoma.

The second paper by Damato and associates (p 109) describes the risk factors for metastatic uveal melanoma after trans-scleral local resection. As acknowledged by the authors, it is not surprising that advanced age, more malignant cell type, and greater tumour diameter were significantly associated with eventual metastasis. The association of superior location of the tumour with eventual metastasis is curious and difficult to explain. It is of interest that lack of adjunctive plaque radiotherapy was also associated with increased chance of metastasis. This again supports the argument for considering combined treatments in the initial therapeutic plan.

Since removal of posterior uveal tumours by local resection is a difficult and time consuming procedure which requires more complicated postoperative care, one may question the advisability of local resection in cases where there is little hope for any useful vision in the affected eye. Although in these latest papers the authors do not elaborate on their current indications for trans-scleral resection, the data that they present in these and earlier publications may provide insight as to when this procedure should be employed. This information would be of value to physicians who may employ local resection or who may wish to refer patients for that procedure. Based on their
results and our personal experience, I would like to
describe briefly what we believe to be the current relative
indications and contraindications for local resection of
ciliary body and choroidal melanoma. It is stressed that
this represents a personal viewpoint which may differ
somewhat from that of Damato and associates and other
clinicians who may use local resection of posterior uveal
melanoma.

The indications for local resection will necessarily vary
from patient to patient and each case must be individualised
depending on the entire clinical situation. However, in
general, local resection should be considered when the
patient is middle aged or younger, and when the tumour has
a more anterior location, greater thickness, smaller base,
and is located on the nasal side of the eye. Tumours located
near the optic disc and foveola, those with lesser thickness,
larger base, and located on the temporal side are likely to be
associated with considerable visual impairment following
local resection and, in such cases, other methods such as
radiotherapy or enucleation should be considered. Younger
individuals tend to tolerate better the hypertensive anaes-
thesia and have less vascular disease that might contribute to
intraoperative or postoperative bleeding. Furthermore, the
gelatinous vitreous in younger patients provides better
retinal tamponade. Tumours with greater basal diameter
and less thickness are best treated with radioactive plaques,
perhaps combined with laser or thermotherapy.

When the patient is older, has systemic vascular disease,
is taking systemic anticoagulants or when the tumour has a
larger base, less thickness, and is more posteriorly located,
it may be more advisable to recommend plaque radio-
therapy or enucleation. Local resection in such cases is
more difficult and more likely to result in intraoperative
and postoperative complications such as vitreous haemor-
rhage, subretinal haemorrhage, retinal detachment, and
severe visual impairment. In addition, the reports of
Damato and associates suggest that local recurrence and
systemic metastasis may be greater in such cases.

More specifically, we believe that local resection can be
favoured when the patient is less than 65 years of age and
in good health; the tumour thickness is greater than 8 mm,
its diameter is less than 15 mm, its posterior margin is
more than 4 mm from the foveola and 3 mm from the optic
disc, and has a nasal location. We believe that local
resection is relatively contraindicated for patients older
than 65 years, when the tumour is less than 8 mm in thick-
ness, more than 15 mm in diameter, less than 4 mm from
the foveola and 3 mm from the optic disc, and has a
temporal location. Most such tumours are best treated
with plaque radiotherapy, thermotherapy, or a combina-
tion of those two methods.

It is quite certain that most posterior uveal melanomas
will continue to be managed by radiotherapy or enucle-
ation and that local resection will be reserved for cases that
meet the relatively strict criteria outlined above. However,
we believe currently that local resection has a definite place
in the management of selected posterior uveal melanomas
and that there are frequent instances where it is clearly
the treatment of choice. However, the surgery is very dif-
ficult and there are numerous potential complications.
Therefore, this procedure should only be performed at
institutions where there are experienced surgeons who
have the frequent opportunities to perform such surgery. It
is quite likely that more patients undergoing local resection
for uveal melanoma will receive supplemental treatment
with radiotherapy, photocoagulation, thermotherapy, or
other adjunctive measures in the future. Foulds and
Damato have pioneered the development and perfection
of local resection of uveal melanoma and they are to be con-
gratulated for their continued contributions.

Supported by the Eye Tumor Research Foundation, Philadelphia, PA, USA.

JERRY A SHIELDS

Ocular Oncology Service,
Wills Eye Hospital,
Thomas Jefferson University,
Philadelphia, USA

1. Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye contain-
ing a malignant melanoma prevent or accelerate the dissemination of
3. Shields JA, Shields CL. Surgical approach to lamellar sclerectomy for
posterior uveal melanomas. The 1986 Schoenberg lecture. Ophthal-
4. Shields JA, Shields CL, Shah P, Sivalingam V. Partial lamellar sclerovec-
tomy for ciliary body and choroidal tumours. Ophthalmology 1991; 98:
971–83.
5. Foulds WS, Damato BE. Low-energy long-exposure laser therapy in the
management of choroidal melanoma. Graefes Arch Clin Exp Ophthal-
6. Oosterhuis JA, Journée-de Korver H, Kakebeeke-Keeme HM, Bleeker JC.
Transpupillary thermotherapy in choroidal melanoma. Arch Ophthal-
Local resection of posterior uveal melanoma.

J A Shields

doi: 10.1136/bjo.80.2.97

Updated information and services can be found at:
http://bjo.bmj.com/content/80/2/97.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/